1. Home
  2. BNR vs SLN Comparison

BNR vs SLN Comparison

Compare BNR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$9.02

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.81

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
SLN
Founded
2014
1994
Country
China
United Kingdom
Employees
N/A
116
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.7M
236.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BNR
SLN
Price
$9.02
$6.81
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$42.60
AVG Volume (30 Days)
10.1K
174.2K
Earning Date
06-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$4.19
52 Week High
$41.72
$8.40

Technical Indicators

Market Signals
Indicator
BNR
SLN
Relative Strength Index (RSI) 20.79 52.19
Support Level $7.99 $5.76
Resistance Level $9.70 $7.53
Average True Range (ATR) 1.17 0.58
MACD -0.72 0.01
Stochastic Oscillator 2.40 66.18

Price Performance

Historical Comparison
BNR
SLN

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: